Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

NervGen Pharma Corp.

NGENFPNK
Healthcare
Biotechnology
$4.15
$-0.06(-1.43%)
U.S. Market opens in 9h 43m

NervGen Pharma Corp. Fundamental Analysis

NervGen Pharma Corp. (NGENF) shows weak financial fundamentals with a PE ratio of -16.09, profit margin of 0.00%, and ROE of -974.60%. The company generates N/A in annual revenue with weak year-over-year growth of 0.00%.

Key Strengths

PEG Ratio-2.23

Areas of Concern

ROE-974.60%
Operating Margin0.00%
Cash Position3.75%
Current Ratio0.79
We analyze NGENF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -97436.1/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-97436.1/100

We analyze NGENF's fundamental strength across five key dimensions:

Efficiency Score

Weak

NGENF struggles to generate sufficient returns from assets.

ROA > 10%
-1.97%

Valuation Score

Excellent

NGENF trades at attractive valuation levels.

PE < 25
-16.09
PEG Ratio < 2
-2.23

Growth Score

Weak

NGENF faces weak or negative growth trends.

Revenue Growth > 5%
0.00%
EPS Growth > 10%
5.26%

Financial Health Score

Moderate

NGENF shows balanced financial health with some risks.

Debt/Equity < 1
-0.01
Current Ratio > 1
0.79

Profitability Score

Weak

NGENF struggles to sustain strong margins.

ROE > 15%
-97459.80%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is NGENF Expensive or Cheap?

P/E Ratio

NGENF trades at -16.09 times earnings. This suggests potential undervaluation.

-16.09

PEG Ratio

When adjusting for growth, NGENF's PEG of -2.23 indicates potential undervaluation.

-2.23

Price to Book

The market values NervGen Pharma Corp. at -141.19 times its book value. This may indicate undervaluation.

-141.19

EV/EBITDA

Enterprise value stands at -18.13 times EBITDA. This is generally considered low.

-18.13

How Well Does NGENF Make Money?

Net Profit Margin

For every $100 in sales, NervGen Pharma Corp. keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $-974.60 in profit for every $100 of shareholder equity.

-974.60%

ROA

NervGen Pharma Corp. generates $-1.97 in profit for every $100 in assets, demonstrating efficient asset deployment.

-1.97%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-0.23 in free cash annually.

$-0.23

FCF Yield

NGENF converts -3.73% of its market value into free cash.

-3.73%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-16.09

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-2.23

vs 25 benchmark

P/B Ratio

Price to book value ratio

-141.19

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-0.01

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.79

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-974.60

vs 25 benchmark

ROA

Return on assets percentage

-1.97

vs 25 benchmark

ROCE

Return on capital employed

6.35

vs 25 benchmark

How NGENF Stacks Against Its Sector Peers

MetricNGENF ValueSector AveragePerformance
P/E Ratio-16.0929.45 Better (Cheaper)
ROE-97459.80%779.00% Weak
Net Margin0.00%-24936.00% (disorted) Weak
Debt/Equity-0.010.26 Strong (Low Leverage)
Current Ratio0.794.65 Weak Liquidity
ROA-197.42%-19344.00% (disorted) Weak

NGENF outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews NervGen Pharma Corp.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

0.00%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

4.45%

Industry Style: Defensive, Growth, Innovation

Growing

FCF CAGR

19.94%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ